What investigations are needed to determine whether a fungal ball represents chronic cavitary pulmonary aspergillosis (CCPA)?

Investigations to Diagnose CCPA

To determine whether a fungal ball represents chronic cavitary pulmonary aspergillosis (CCPA), you need three core components: CT imaging showing one or more cavities with radiological progression over ≥3 months, serological or microbiological evidence of Aspergillus infection, and exclusion of alternative diagnoses 1.

Required Investigations

1. Imaging Studies

• CT scan of the thorax (preferred over chest radiography alone)
  • Look for one or more pulmonary cavities with thin or thick walls
  • May contain aspergillomas (fungal balls) or irregular intraluminal material
  • Document radiological progression: new cavities, increasing pericavitary infiltrates, or increasing fibrosis over at least 3 months 1
  • Cavity wall thickening is a key distinguishing feature (high positive likelihood ratio for aspergilloma) 2
  • Serial imaging is essential—CCPA requires documented progression, unlike simple aspergilloma which shows no progression 1

2. Serological Testing

• Aspergillus IgG antibody or precipitins (positive in >90% of CCPA cases)
  • This is the cornerstone diagnostic test 1, 3
  • If a fungal ball is visible on imaging, a positive Aspergillus IgG alone confirms Aspergillus as the causative organism 1
  • Combination of positive Aspergillus IgG with cavity wall thickening on CT has 71.4% sensitivity and 87.5% specificity 2

3. Microbiological Evidence (if serology negative or additional confirmation needed)

Any of the following 1:

• Respiratory fluid testing:

  • Strongly positive Aspergillus galactomannan antigen in BAL or sputum
  • Aspergillus DNA detection (PCR) in respiratory fluids
  • Sputum or BAL culture growing Aspergillus species

• Tissue sampling (if accessible and safe):

  • Percutaneous or bronchoscopic biopsy showing fungal hyphae on microscopy 1, 4
  • Culture from cavity material
  • Critical distinction: If hyphae are seen invading lung parenchyma, this indicates subacute invasive aspergillosis, not CCPA 1

4. Clinical Assessment

• Duration: Symptoms present for ≥3 months 1
• Symptoms to document: Chronic cough, hemoptysis, weight loss, fatigue, breathlessness 1, 5
• Inflammatory markers: Elevated ESR, CRP (typically raised in CCPA) 5
• Immunocompetence status: CCPA occurs in non-immunocompromised patients (or those on ≤10 mg prednisolone daily) 1

5. Exclusion of Alternative Diagnoses

Must rule out 1:

• Active tuberculosis (can coexist with CCPA)
• Non-tuberculous mycobacterial infection
• Lung cancer (especially in cavitary lesions)
• Other fungal infections

Diagnostic Algorithm

Step 1: Obtain CT thorax and document cavity characteristics and any progression over time

Step 2: Order Aspergillus IgG/precipitins

• If positive + fungal ball visible → diagnosis confirmed
• If positive + cavities without fungal ball + symptoms ≥3 months + radiological progression → CCPA diagnosed

Step 3: If serology negative, obtain respiratory samples (sputum, BAL) for:

• Aspergillus galactomannan
• Aspergillus PCR
• Fungal culture

Step 4: Consider bronchoscopic biopsy if diagnosis remains uncertain and patient can tolerate procedure 4

Step 5: Exclude TB, NTM, and malignancy through appropriate testing

Key Distinguishing Features

CCPA vs. Simple Aspergilloma 1:

• CCPA: Multiple cavities OR single cavity with significant symptoms AND radiological progression over ≥3 months
• Simple aspergilloma: Single cavity, minimal/no symptoms, NO radiological progression over ≥3 months

Common Pitfalls

• Don't rely on chest radiography alone—CT is essential for accurate diagnosis 6
• Don't assume negative sputum culture excludes CCPA—serology is more sensitive 2, 4
• Don't forget serial imaging—progression over time is a defining criterion 1
• Don't miss coexistent TB or NTM—these can occur simultaneously with CCPA 3
• Absence of cavitation on chest X-ray has 100% negative predictive value for CPA, but CT is still needed for positive diagnosis 6